What is the half-life of FGL(L)?

FGL(L) has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute FGL(L)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

What is the half-life of FGL(L)?

FGL(L) has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute FGL(L)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Phase 1

FGL(L)

Also known as: FGL peptide, FG Loop peptide, NCAM mimetic peptide

Overview

Key Facts

Primary Goal: Research and therapeutic applications of FGL(L)

Binds and activates FGFR1, triggering downstream MAPK/ERK and PLCgamma signaling cascades. Mimics the NCAM-FGFR1 interaction that is critical for synaptic plasticity and memory consolidation.

Dosing Information

Half-Life

~2-4 hours (estimated from preclinical data)

Typical Dose

500–2000 mcg

Frequency

every 2-3 days

Cycle Length

4-8 weeks

Administration Routes:

subcutaneous

Benefits

Promotes neurite outgrowth and synaptogenesis
Enhanced long-term potentiation (LTP) in hippocampal circuits
Improved spatial memory and learning in animal models
Anti-inflammatory effects in CNS tissue
Neuroprotective in Alzheimer's disease models

Side Effects

Limited human safety data (early Phase I)uncommonmild

Injection site irritationuncommonmild

Theoretical risk of aberrant neural growth at excessive dosesuncommonmild

Possible immune response with prolonged administrationuncommonmild

Mechanism of Action

Binds and activates FGFR1, triggering downstream MAPK/ERK and PLCgamma signaling cascades

Mimics the NCAM-FGFR1 interaction that is critical for synaptic plasticity and memory consolidation

Promotes presynaptic and postsynaptic structural remodeling

Reduces microglial activation and neuroinflammation through FGFR1-mediated anti-inflammatory signaling

Contraindications

Do not use this peptide if any of the following apply:

Active CNS malignancy (FGFR1 involvement in certain tumours)
Pregnancy or breastfeeding
No established human dosing guidelines — research use only

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 1

FGL(L) was developed by researchers at the University of Copenhagen and ENKAM Pharmaceuticals. Published studies in the Journal of Neuroscience and Neurobiology of Disease demonstrated that subcutaneous FGL administration improved spatial memory in rats and enhanced LTP in hippocampal slices. A Phase I clinical trial in healthy elderly volunteers was conducted, establishing preliminary safety and tolerability. Preclinical Alzheimer's models showed FGL reduced amyloid-beta-induced neuronal death and rescued cognitive deficits. The NCAM-mimetic approach represents a unique mechanism for cognitive enhancement distinct from neurotransmitter-based strategies.

Frequently Asked Questions

Common questions about FGL(L)

UK-Specific Information

Exclusive data points and guidance for UK residents using FGL(L)

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Generate a trackable link to share this peptide information on TikTok